Quantum-Si, Inc. (QSI)
NASDAQHealth CareMedical - DevicesSnapshot 2026-10-29
$1.46-16.57%
Close 2026-10-30 · 1-day change
NASDAQHealth CareMedical - DevicesSnapshot 2026-10-29
Research Workspace
Put QSI beside peers and holdings, graph the same metric, and keep your notes with the evidence.
Daily closes. Earnings/event dots are placed inline.
Industries move in repeating boom-and-bust cycles. This shows where this stock’s industry sits in that cycle, stage by stage (recovery → expansion → supercycle → steady → deceleration → contraction), from its fundamentals (orders, revenue, capital spending), not the stock’s price.
A booming industry is a tailwind for the names in it; a contracting one is a headwind. Companies in the same industry tend to rise and fall together with the cycle, the way a tide lifts and lowers every boat in the harbor at once, so a large part of a stock’s swing can come from where its industry sits rather than from the company itself. It’s context for reading the company’s results, not a buy/sell call. Full explanation →
Health Care Equipment: fringe margins under pressure (4q confirmed)
The stage band shows the industry’s cycle over the chart’s timeline (each color a stage); a ▼ marks a quarter its growth inflected down — amber is an unconfirmed watch, red is confirmed the next quarter. Use “Overlay cycle on chart” to tint the price chart by stage. The industry’s fundamentals, not a signal on this stock.
Primary pillar under pressure — Limit total cash usage to $93 million in 2026: Comparison needs review.
View ThesisRevenue is contracting — down about 53% over the past year.
View GrowthManagement screens weak on capital allocation, margins, market reaction to earnings.
View ManagementExpectations look high — what the market is pricing in runs ahead of what analysts forecast.
View ValuationThis stock is highly volatile — it swings about 3% on a typical day and fell roughly 67% in its worst 12-month stretch.
View RiskQSI’s amino acid detection progress must gain traction to support its sales-based valuation. Revenue fell 42% year over year in Q2 FY2026, despite an earnings beat. QSI trades at 198× sales versus the 3× peer median, with expectations pricing in more growth than we forecast. Its own historical multiple was 103×. The risk is that this premium compresses before the growth is demonstrated. Our model puts the next-quarter miss probability near 30%. Peer multiples imply a price about 75% below where it trades; the thesis is on watch, and this read is provisional.
Trailing returns as of 2026-10-30. QSI is total return (includes dividends); the S&P 500 benchmark is price return (the index excludes dividends).
Based on 3 analysts currently covering QSI (as of Oct 2026).
Analyst ratings and price targets are third-party Wall Street estimates, not QuarterlyIQ’s view. Not investment advice.
Continue this research
Compare QSI with peers and holdings, graph the same reported metric, keep your questions beside the evidence, and return when the facts change.
Compare now without an account. Saving and monitoring require an account.
| Compare | Company | Living FV | P/E | Revenue % | Quality |
|---|---|---|---|---|---|
| QSI Selected company | Graph | Compare | Trend | Review | |
| Peer Add a competitor | Graph | Compare | Trend | Review | |
| Holding Compare a holding | Graph | Compare | Trend | Review |
Selected metric trend
Quarterly · checked companies · value or % of revenue
A consensus fair price across 0 valuation methods, at three horizons. As of 2026-10-29. Estimates are diagnostics, not price targets. Short-horizon estimates are close to coin-flips, so confidence is a method-agreement read, not a prediction.
Today's peer multiple on trailing earnings, with no growth credited. This is the headline read.
Adds projected growth, so it leans optimistic by design. Read it as upside context, not a base case.
A price-focused, side-by-side fair-value read versus Health Care Equipment — fair value, gap to price, and forward P/E.
Compare the value case
Put QSI next to peers and holdings, compare Living FV and multiples, then graph the driver behind the difference.
Threatens: Commercial launch of Proteus platform in Q2 2027
Delay in Proteus launch impacts growth objectives.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
End-of-day figures as of 2026-10-30. EPS is implied from price ÷ P/E. Not investment advice.
A long-thesis check that carries the widest uncertainty of the three horizons.
Below average on quality vs scored peers
Direction of the business behind the multiple. Bands are backend reads; trailing-12-month basis.
TTM earnings are negative. P/E-based methods drop out and the estimate leans on sales- and cash-flow-based methods. A data condition, not a forward call.
Advances: Extend cash runway into Q4 2028 through cost reductions
$12M opex savings extend cash runway.
Advances: Achieve approximately $1M revenue in 2026
Earnings beat indicates strong revenue potential for 2026.
